Key Takeaways From Vivus' Bad Quarter
Nov 8th 2013 6:03PM
Updated Nov 8th 2013 6:04PM
From the smallest biotech to the biggest pharmaceutical stock, The Motley Fool's Market Checkup covers the health-care sector's biggest headlines, hottest market movers, and Obamacare's ongoing rollout.
In this segment from Thursday's episode, health-care analyst David Williamson takes a look at the third-quarter earnings report from Vivus . Shares fell more than 12% on the news that the company's revenue from its drug Qsymia was nowhere near what investors were hoping for. While the company showed 35% quarter-to-quarter growth, this, too, fell drastically short of the exponential growth investors were hoping for from a pharmaceutical company with a potentially blockbuster new drug rollout. David looks closely into Vivus' prospects, and lists a few other headwinds investors should be aware of.
Two game-changing biotechs
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report, "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.
Follow David on Twitter: @MotleyDavid.
The article Key Takeaways From Vivus' Bad Quarter originally appeared on Fool.com.Alison Southwick has no position in any stocks mentioned. David Williamson has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.